Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIC-1911, PTCy, and Sirolimus for GVHD Prevention in Children After Haplo HSCT
NCT07350057Phase 1Recruiting
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Sep 2026
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TAS-119 in graft-versus-host disease (GVHD), sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoint: Recommended Phase 2 Dose at 2 years. Started Sep 2026; status: recruiting.
02
Drugs
TAS-119
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT07350057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07350057.